Pooled Phase III Data Supporting Perampanel Partial Epilepsy Treatment
New data shared today with Europe's epilepsy community at the 10th European Congress on Epileptology (ECE) in London, demonstrated the efficacy of Fycompa(R) (perampanel) in reducing partial-onset seizures, the most common form of epilepsy, and its effectiveness and flexibility of use as add-on therapy. The successful treatment of partial-onset seizures (the most common form of epilepsy) remains a significant challenge in some patients and the incidence of uncontrolled partial epilepsy remains high, despite many existing anti-epileptic drugs (AEDs); between 20 - 40% of patients with epilepsy have remained poorly controlled despite these treatments.[1] The new data supports the use of perampanel as a new therapeutic option for this hard-to-treat patient population. read more